Gliclazide microcrystals prepared by two methods of in situ micronization: Pharmacokinetic studies in diabetic and normal rats

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 786-792

  Talari, Roya ^a,c   Varshosaz, Jaleh ^a   Mostafavi, Saied Abolfazl ^a   Nokhodchi, Ali ^b,d  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^c Research Center   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Gliclazide; In situ micronization; Microcrystals; Pharmacokinetics

Indexed keywords

GLICLAZIDE; INSULIN; SOLVENT; ANTIDIABETIC AGENT; ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG SOLUBILITY; DRUG SYNTHESIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; ANIMAL; COMPARATIVE STUDY; CRYSTALLIZATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG FORMULATION; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES; TREATMENT OUTCOME; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; CRYSTALLIZATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG COMPOUNDING; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; IONS; MALE; METABOLIC CLEARANCE RATE; PARTICLE SIZE; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 77955672121     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9441-9     Document Type: Article

References (34)

1. Orienti I, Bigucci F, Luppi B, Cerchiara T, Zuccari G, Giunchedi P et al. Polyvinylalcohol substituted with triethyleneglycolmonoethylether as a new material for preparation of solid dispersion of hydrophobic drugs. Eur J Pharm Biopharm. 2002;54:229-33.
2. Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000;50:3-12.
3. Sarkari M, Brown J, Chen X, Swinnea S, William RO, Johnston KP. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int J Pharm. 2002;243:17-31.
4. Gibson M. Pharmaceutical preformulation and formulation-a practical guide from candidate drug selection to commercial dosage form. Englewood: HIS Health Group; 2001.
5. Kim ST, Kwon JH, Lee JJ, Kim CW. Microcrystallization of indomethacin using a pH-shift method. Int J Pharm. 2003;263(1-2):141-50.
6. Chaumeil JC. Micronization: a method of improving the bioavailability of poorly soluble drugs. Meth Find Exp Clin Pharmacol. 1998;20:211-5.
7. Rasenack N, Muller BW. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res. 2002;19(12):1894-900.
8. Steckel H, Rasenack N, Muller BW. In situ micronization of disodiumcromoglycate for pulmonary delivery. Eur J Pharm Biopharm. 2003;55:173-80.
9. Williams III RO, Brown J, Liu J. Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation. Pharm Dev Tech. 1999;4(2):167-79.
10. Huang QP, Wang JX, Chen GZ, Shen ZG, Chen JF, Yun J. Micronization of gemfibrozil by reactive precipitation process. Int J Pharm. 2008;360:58-64.
11. Zhang HX, Wang JX, Zhang ZB, Le Y, Shen ZG, Chen JF. Micronization of atorvastatin calcium by antisolvent precipitation process. Int J Pharm. 2009;374(1-2):106-13.
12. Giry K, Pean JM, Giraud L, Marsas S, Rolland H, Wuthrich P. Drug/lactose co-micronization by jet milling to improve aerosolization properties of a powder for inhalation. Int J Pharm. 2006;321:162-6.
13. Moribe K, Tsutsumi S, Morishita S, Shinozaki H, Tozuka Y, Oguchi T et al. Micronization of phenylbutazone by rapid expansion of supercritical CO2 solution. Chem Pharm Bull. 2005;53(8):1025-8.
14. Betageri GV, Makarla KR. Enhancement of dissolution of glyburide by solid dispersion and lyophylization techniques. Int J Pharm. 1995;126:155-60.
15. Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs. 1993;46:93-125.
16. Arias-Blanco MJ, Moyano JR, Perez-Martinez JI, Gines JM. Study of the inclusion of GL in α-cyclodextrin. J Pharm Biomed Anal. 1998;18:275-9.
17. Ozkan Y, Atay T, Dikmen N, Isimer A, Aboul-Enein HY. Improvement of water solubility and in vitro dissolution rate of GL by complexation with β-cyclodextrin. Pharm Act Helv. 2000;74:365-70.
18. Aggarwal S, Singh PN, Mishra B. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes. Pharmazie. 2002;57(3):191-3.
19. Moyano JR, Arias-Blanco MJ, Gines JM, Rabasco AM, Perez-Martinez JI, Mor M et al. Nuclear magnetic resonance investigation of the inclusion complexation of GL with β-cyclodextrin. J Pharm Sci. 1997;86(1):72-5.
20. Varshosaz J, Talari R, Mostafavi A, Nokhodchi A. Dissolution enhancement of gliclazide using in situ micronization by solvent change method. Powder Tech. 2008;187:222-30.
21. Talari R, Varshosaz J, Mostafavi A, Nokhodchi A. Dissolution enhancement of gliclazide using pH change approach in Presence of Twelve Stabilizers with Various Physico-Chemical Properties. J Pharm Pharmaceutic Sci. 2009;12(3):250-65.
22. Rouini MR, Mohajer A, Tahami MH. A simple and sensitive HPLC method for determination of gliclazide in human serum. J Chromatography B. 2003;785:383-6.
23. Jaiswal D, Rai PK, Kumar A, Mehta S, Watal G. Effect of Moringa oleifera Lam. Leaves aqueous extract therapy on hyperglycemic rats. J Ethnopharmacol. 2009;123(3):392-6.
24. Weiss J, Taylor GR, Zimmermann F, Nebendahl K. Collection of body fluids. In: Krinke GJ, editor. The handbook of experimental animals, the laboratory rat. San Diego: Academic; 2000. p. 488-9.
25. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982. p. 149-51.
26. Pandikumar P, Prakash Babu N, Ignacimuthu S. Hypoglycemic and antihyperglycemic effect of Begonia malabarica Lam. in normal and streptozotocin induced diabetic rats. J Ethnopharmacol. 2009;124:111-5.
27. Kuo CY, Wu SM. High-performance liquid chromatography with electrochemical detection for analysis of gliclazide in plasma. J Chromatogr A. 2005;1088:131-5.
28. Poirier JM, Perez M, Cheymol G. High-performance liquid chromatographic determination of gliclazide in human plasma. J Chromatogr. 1987;421:223-6.
29. Charles BG, Ravenscroft PJ. Measurement of gliclazide in plasma by radial compression reversed-phase liquid chromatography. Clin Chem. 1984;30:1789-91.
30. Yu NH, Ho E N M, Tang F P W, Wan T S M, Wong A S Y. Comprehensive screening of acidic and neutral drugs in equine plasma by liquid chromatography-tandem mass spectrometry. J Chrom A. 2008;1189:426-34.
31. Varshosaz J, Tavakoli N, Minayian M, Rahdari N. Applying the Taguchi design for optimized formulation of sustained-release gliclazide chitosan beads: an in vitro/in vivo study. AAPS Pharm Sci Tech. 2009;10(1):158-65.
32. Tanira M O M, Furman BL. The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat. Pharmacol Res. 1999;39:349-56.
33. Gholamhoseinian A, Fallah H, Sharififar F. Inhibitory effect of methanol extract of Rosa damascena Mill. Flowers on α-glucosidase activity and postprandial hyperglycemia in normal and diabetic rats. Phytomedicine. 2009;16(10):935-41.
34. Cunha WR, Arantes GM, Ferreira DS, Lucarini R, Silva M L A, Furtado N A J C et al. Hypoglycemic effect of Leandra lacunosa in normal and alloxan-induced diabetic rats. Fitoterapia. 2008;79:356-60.